U.S. markets open in 1 hour 14 minutes
  • S&P Futures

    4,694.75
    +9.75 (+0.21%)
     
  • Dow Futures

    35,775.00
    +62.00 (+0.17%)
     
  • Nasdaq Futures

    16,360.00
    +42.00 (+0.26%)
     
  • Russell 2000 Futures

    2,263.20
    +9.30 (+0.41%)
     
  • Crude Oil

    72.31
    +0.26 (+0.36%)
     
  • Gold

    1,783.70
    -1.00 (-0.06%)
     
  • Silver

    22.37
    -0.15 (-0.68%)
     
  • EUR/USD

    1.1307
    +0.0034 (+0.31%)
     
  • 10-Yr Bond

    1.4800
    0.0000 (0.00%)
     
  • Vix

    21.73
    -5.45 (-20.05%)
     
  • GBP/USD

    1.3194
    -0.0048 (-0.36%)
     
  • USD/JPY

    113.7910
    +0.2510 (+0.22%)
     
  • BTC-USD

    49,240.44
    -1,859.43 (-3.64%)
     
  • CMC Crypto 200

    1,285.77
    -35.51 (-2.69%)
     
  • FTSE 100

    7,350.68
    +10.78 (+0.15%)
     
  • Nikkei 225

    28,860.62
    +405.02 (+1.42%)
     

Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021, at 1:00 p.m. ET.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
rflamm@burnsmc.com / hwong@burnsmc.com
(212) 213-0006 ext. 364 / 316